東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

What drives R&D alliances? Evid...

Han, Yongliang.

Linked to FindBook

Google Book

Amazon

博客來

What drives R&D alliances? Evidence from the biotechnology industry.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	What drives R&D alliances? Evidence from the biotechnology industry./
Author:	Han, Yongliang.
Description:	116 p.
Notes:	Adviser: Julia Porter Liebeskind.
Contained By:	Dissertation Abstracts International63-12A.
Subject:	Business Administration, Management. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3073787
ISBN:	0493938729

What drives R&D alliances? Evidence from the biotechnology industry.
Han, Yongliang.

What drives R&D alliances? Evidence from the biotechnology industry. - 116 p.

Adviser: Julia Porter Liebeskind.

Thesis (Ph.D.)--University of Southern California, 2002.

In this dissertation, we examine the motives for R&D alliances formed by large pharmaceutical companies (LPCs) with new biotechnology firms (NBFs). Using a sample of 638 R&D alliances formed by 15 global pharmaceutical firms between 1985 and 1998, we test three distinct but related explanations for R&D alliances in biotechnology. These include the transaction cost explanation; learning with flexibility; and technology preemption.

ISBN: 0493938729Subjects--Topical Terms:

626628
Business Administration, Management.

What drives R&D alliances? Evidence from the biotechnology industry.
LDR:01974nam 2200277 a 45 001 926928
005 20110422
008 110422s2002 eng d
020 $a 0493938729
035 $a (UnM)AAI3073787
035 $a AAI3073787
040 $a UnM $c UnM
100 1 $a Han, Yongliang. $3 1250511
245 1 0 $a What drives R&D alliances? Evidence from the biotechnology industry.
300 $a 116 p.
500 $a Adviser: Julia Porter Liebeskind.
500 $a Source: Dissertation Abstracts International, Volume: 63-12, Section: A, page: 4380.
502 $a Thesis (Ph.D.)--University of Southern California, 2002.
520 $a In this dissertation, we examine the motives for R&D alliances formed by large pharmaceutical companies (LPCs) with new biotechnology firms (NBFs). Using a sample of 638 R&D alliances formed by 15 global pharmaceutical firms between 1985 and 1998, we test three distinct but related explanations for R&D alliances in biotechnology. These include the transaction cost explanation; learning with flexibility; and technology preemption.
520 $a We conduct extensive demographic analyses to explore issues including the patterns of the development of LPCs' internal R&D capabilities in biotechnology, their R&D alliance formation behavior, and the relationship between these activities over time. We seek to interpret empirical evidence in the light of the three explanations for the motives behind R&D alliances. The results presented in this study seem to be consistent with the argument that LPCs' alliances with NBFs are motivated primarily by their need to learn while retaining organizational flexibility. The other two explanations receive only weak support.
590 $a School code: 0208.
650 4 $a Business Administration, Management. $3 626628
690 $a 0454
710 2 0 $a University of Southern California. $3 700129
773 0 $t Dissertation Abstracts International $g 63-12A.
790 $a 0208
790 1 0 $a Liebeskind, Julia Porter, $e advisor
791 $a Ph.D.
792 $a 2002
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3073787